Aug 27, 2026 10:15AM

Jun 11, 2026 02:20AM

Mar 26, 2026 09:32AM

Mar 26, 2026 08:53AM

Feb 15, 2026 07:10PM

Jun 1, 2024 08:17PM

Jan 2, 2022 07:00PM CStone Pharmaceuticals announced the IND approval of CS5001, a potential global best-in-class ROR1-targeting ADC by the U.S. Food and Drug Administration

Dec 22, 2021 08:05AM

Dec 22, 2021 08:00AM

Dec 21, 2021 03:44AM

Jul 26, 2021 06:00AM

Jun 21, 2021 08:07AM

Jun 21, 2021 08:03AM

May 28, 2021 06:00AM Primary Endpoint Met in Phase 3 Study of the Anti-PD-L1 Antibody Sugemalimab in Stage III Non-Small Cell Lung Cancer

May 27, 2021 08:10PM

Oct 26, 2020 07:23PM

Sep 25, 2020 06:00AM

Aug 30, 2020 11:15PM

Aug 18, 2020 09:27PM

Aug 7, 2020 08:38AM

Aug 7, 2020 08:30AM CStone Announces That OmniAb-derived CS1001 (Anti-PD-L1) Phase 3 Trial Met the Primary Endpoint as First-Line Treatment in Stage IV Squamous and Non-squamous Non-Small Cell Lung Cancer and Announces P

Apr 23, 2020 12:45AM

Apr 22, 2020 08:57PM

Mar 27, 2020 02:02AM

Mar 26, 2020 07:30AM

Mar 26, 2020 06:25AM

Jan 23, 2020 07:03PM

Jan 6, 2020 08:00AM CStone Pharmaceuticals and Blueprint Medicines Initiate Phase 1b/2 Clinical Trial of Fisogatinib in Combination with CS1001 for Patients with Hepatocellular Carcinoma

Dec 10, 2019 09:38PM

Nov 19, 2019 10:30PM

Aug 26, 2019 03:50AM

Aug 22, 2019 11:24PM

Aug 22, 2019 11:21PM

Aug 13, 2019 12:21AM

Jul 22, 2019 12:17AM CStone receives approval in China to initiate ivosidenib Phase I bridging registrational study for the treatment of IDH1 mutant relapsed or refractory AML

Jul 9, 2019 10:23PM

Jun 5, 2019 07:56AM

Jun 2, 2019 11:45PM

May 23, 2019 06:01AM

Apr 15, 2019 02:32AM

Apr 4, 2019 11:44AM

Mar 25, 2019 03:14AM CStone appoints three distinguished oncology leaders Drs. Paul A. Bunn, Jr., Elizabeth M. Jaffee and Richard S. Finn to its Scientific Advisory Board

Mar 21, 2019 09:32AM

333,559 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All